Replies to post #98898 on Savvy Trades and Investments

[swampboots]

NEXI: I like DTIL better 1.53, both do allogeneic cell therapy,, both have some insider buying, but DTIL has revenue ,partners and cash to 2024 as just did the dilutive pipe sure shot dive.
I am no scientist so have to believe Novartis and Lilly picked over the important substance only computation rigor could discern.

[RNsidersbuying]

ELEV 1.48 - pound-for-pound this is the best value I'm seeing right now in the biobust sector.

BV = 5.40
Burn = (.75)

NEXI is at the top of my watchlist...